Siemens Medical Systems’ Ultrasound Group filled a gap in its Sonoline ultrasound family with the 1999 RSNA introduction of Omnia, a high-end multispecialty imaging system. Omnia, which includes several advanced technology features found on
Siemens Medical Systems Ultrasound Group filled a gap in its Sonoline ultrasound family with the 1999 RSNA introduction of Omnia, a high-end multispecialty imaging system. Omnia, which includes several advanced technology features found on Siemens flagship Elegra scanner, will have a price range of $95,000 to $130,000. The Issaquah, WA-based firm has not previously offered a system at that price point.
Available on all of Omnias transducers is black and white SieScape panoramic imaging. Also included is Ensemble Tissue Harmonic Imaging, which is designed to enhance gray-scale contrast resolution, especially in difficult-to-scan patients, according to the company.
Omnia shares the same architecture as the Elegra scanner, including Siemens Crescendo multidimensional image processor. This allows for easy integration of further advanced technology into Omnia in the future, according to Wolfgang Reim, president of Siemens Ultrasound.
Siemens believes Omnia is appropriate for general imaging, shared service cardiology, obstetrics/gynecology, small parts, vascular, pediatrics, urology, and surgical applications. It supports 22 transducers, including such specialty transducers as the high-frequency VF13-5 for breast and musculoskeletal applications. Mechanical and electronic endocavity transducers and a new broadband P4-2 phased-array for cardiac, abdominal, and transcranial imaging are part of the system. C8-5, a neonatal transducer, is designed for use inside isolettes where maneuvering is extremely difficult. The transducer performs such neonatal and pediatric exams as cranial, abdominal, and preliminary cardiac screening.
An internal magneto-optical disk drive provides storage and fast image retrieval for mobile exams. Volume shipments of Omnia are set to begin in February.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.